Collaboration to Accelerate the Discovery of Protein Degrading Therapeutics
EXTON, Pa., April 5, 2018 /PRNewswire/ — Frontage Laboratories Inc., a global CRO with headquarters in Exton, Pennsylvania, announces the acquisition of Concord Biosciences, formerly known as Ricerca Biosciences LLC, a preclinical CRO located near Cleveland, Ohio. Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical and animal health industries with Drug Safety, Metabolism, Bioanalytical, Residue and Environmental Fate studies.
Dr. Song Li, founder and CEO of Frontage Laboratories, said, "We have committed to build a global CRO company with integrated services. The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry."
For more information on this acquisition, visit http://www.frontagelab.com/about/news-item/frontage-acquires-concord-biosciences.
About Concord Biosciences
Founded in 1986, Concord is a contract research organization that supports the pharmaceutical, agricultural and animal health industries. Our comprehensive, integrated suite of services help our clients meet their regulatory requirements and internal development goals. Located on a 20-acre campus in Concord, Ohio, our expansive facilities allow for Concord to operate on the scale of a large CRO, while offering the nimbleness of a small CRO. Concord is relentless in its pursuit of client service and adding value to client situations through accelerating timelines and providing expert collaboration. For more information, visit http://www.concordbio.com/.
SOURCE Frontage Laboratories Inc.